Mologic and Alamar team up to fight future threats from Covid

Mologic in Bedford UK and Maine in the US and Alamar Biosciences in California are partnering on the project.

The collaboration will utilise Alamar’s novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.

Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (COVIOS and COVIGO for personal self-testing) based on its lateral flow assay technology, utilising high affinity, paired antibodies specific for the SARS-CoV-2 nucleoprotein antigen.  Read more

Related Posts

Business Leaders: Deborah Bronk steers Bigelow Lab expansion to boost reach, programming

Deborah Bronk is president, CEO and a senior research scientist at Bigelow Laboratory for Ocean Sciences in East Boothbay, which will...

24 March 2025

UNE retains R2 Research status, reinforcing leadership in scientific advancement

The University of New England has retained its status as one of the country’s leading research universities with the recent release...

23 March 2025

Maine college students investigate health effects of forever chemicals

Two dozen Maine college students are investigating the public health effects of forever chemicals by using zebrafish as human stand-ins and...

21 March 2025